DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Mercuric chloride

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
LTEA_HepaRG_CYP1A1	Liver	Human	1543	CYP1A1	Activatory	50.0 μM
LTEA_HepaRG_CYP1A2	Liver	Human	1544	CYP1A2	Activatory	50.0 μM
LTEA_HepaRG_GADD45B	Liver	Human	4616	GADD45B	Inhibitory	50.0 μM
LTEA_HepaRG_GADD45G	Liver	Human	10912	GADD45G	Inhibitory	24.07 μM
LTEA_HepaRG_KRT19	Liver	Human	3880	KRT19	Inhibitory	29.27 μM
LTEA_HepaRG_THRSP	Liver	Human	7069	THRSP	Inhibitory	20.52 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CCTE_Deisenroth_5AR_NBTE_ratio	Kidney	Human	6716	SRD5A2	Inhibitory	75.43 μM
CCTE_GLTED_hTBG		Human	6906	SERPINA7	Loss	27.64 μM
NVS_ADME_hCYP1A2		Human	1544	CYP1A2	Loss	1.0 μM
NVS_ADME_hCYP2C19		Human	1557	CYP2C19	Loss	0.81 μM
NVS_ADME_hCYP3A4		Human	1576	CYP3A4	Loss	0.97 μM
NVS_ENZ_hAChE		Human	43	ACHE	Loss	28.29 μM
NVS_ENZ_hES		Human	590	BCHE	Loss	20.91 μM
NVS_GPCR_gBK2	Intestinal	Guinea pig	100135486	Bdkrb2	Loss	25.0 μM
NVS_GPCR_gLTD4	Lung	Guinea pig	100135514	Cysltr1	Loss	1.4 μM
NVS_GPCR_h5HT5A		Human	3361	HTR5A	Loss	1.59 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	1.56 μM
NVS_GPCR_h5HT7		Human	3363	HTR7	Loss	0.93 μM
NVS_GPCR_hAdra2C		Human	152	ADRA2C	Loss	0.23 μM
NVS_GPCR_hAdrb1		Human	153	ADRB1	Loss	0.3 μM
NVS_GPCR_hAdrb2		Human	154	ADRB2	Loss	0.93 μM
NVS_GPCR_hC5a		Human	728	C5AR1	Loss	25.0 μM
NVS_GPCR_hDRD1		Human	1812	DRD1	Loss	0.19 μM
NVS_GPCR_hDRD2s		Human	1813	DRD2	Loss	0.35 μM
NVS_GPCR_hH1		Human	3269	HRH1	Loss	0.95 μM
NVS_GPCR_hM1		Human	1128	CHRM1	Loss	1.47 μM
NVS_GPCR_hM2		Human	1129	CHRM2	Loss	1.48 μM
NVS_GPCR_hM3		Human	1131	CHRM3	Loss	0.58 μM
NVS_GPCR_hM5		Human	1133	CHRM5	Loss	0.43 μM
NVS_GPCR_hNK2		Human	6865	TACR2	Loss	0.84 μM
NVS_GPCR_hOpiate_D1		Human	4985	OPRD1	Loss	0.27 μM
NVS_GPCR_hOpiate_mu		Human	4988	OPRM1	Loss	0.2 μM
NVS_GPCR_hORL1		Human	4987	OPRL1	Loss	0.32 μM
NVS_GPCR_mCKKBCentral	Brain	Mouse	12426	Cckbr	Loss	38.58 μM
NVS_GPCR_rAdrb_NonSelective	Brain	Rat	24925	Adrb1	Loss	35.7 μM
NVS_GPCR_rGABBR	Brain	Rat	81657	Gabbr1	Loss	18.4 μM
NVS_GPCR_rH3	Brain	Rat	85268	Hrh3	Loss	24.61 μM
NVS_IC_rKATPCh	Brain	Rat	24521	Kcnj1	Loss	27.56 μM
NVS_TR_gDAT	Brain	Guinea pig	100714898	Slc6a3	Loss	44.16 μM
NVS_TR_hDAT		Human	6531	SLC6A3	Loss	25.0 μM
NVS_TR_hNET		Human	6530	SLC6A2	Loss	0.37 μM
NVS_TR_rSERT	Brain	Rat	25553	Slc6a4	Loss	25.0 μM
ATG_DR4_LXR_CIS	Liver	Human	7376\|10062	NR1H2\|NR1H3	Inhibitory	33.35 μM
ATG_HIF1a_CIS	Liver	Human	3091	HIF1A	Inhibitory	33.35 μM
ATG_p53_CIS	Liver	Human	7157	TP53	Activatory	55.39 μM
ATG_SREBP_CIS	Liver	Human	6720	SREBF1	Activatory	50.97 μM
BSK_3C_Eselectin	Vascular	Human	6401	SELE	Inhibitory	36.69 μM
BSK_3C_HLADR	Vascular	Human	3122	HLA-DRA	Inhibitory	30.01 μM
BSK_3C_IL8	Vascular	Human	3576	CXCL8	Inhibitory	31.11 μM
BSK_3C_MIG	Vascular	Human	4283	CXCL9	Inhibitory	30.89 μM
BSK_3C_TissueFactor	Vascular	Human	2152	F3	Inhibitory	34.76 μM
BSK_3C_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	34.13 μM
BSK_3C_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	20.0 μM
BSK_4H_Eotaxin3	Vascular	Human	10344	CCL26	Inhibitory	30.92 μM
BSK_4H_MCP1	Vascular	Human	6347	CCL2	Inhibitory	30.74 μM
BSK_4H_Pselectin	Vascular	Human	6403	SELP	Inhibitory	33.03 μM
BSK_4H_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	30.02 μM
BSK_4H_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	29.66 μM
BSK_BE3C_HLADR	Lung	Human	3122	HLA-DRA	Inhibitory	30.16 μM
BSK_BE3C_IL1a	Lung	Human	3552	IL1A	Inhibitory	30.99 μM
BSK_BE3C_IP10	Lung	Human	3627	CXCL10	Inhibitory	34.92 μM
BSK_BE3C_MIG	Lung	Human	4283	CXCL9	Inhibitory	36.5 μM
BSK_BE3C_MMP1	Lung	Human	4312	MMP1	Inhibitory	31.44 μM
BSK_BE3C_PAI1	Lung	Human	5054	SERPINE1	Inhibitory	30.91 μM
BSK_BE3C_TGFb1	Lung	Human	7040	TGFB1	Inhibitory	30.95 μM
BSK_BE3C_tPA	Lung	Human	5327	PLAT	Inhibitory	31.83 μM
BSK_BE3C_uPA	Lung	Human	5328	PLAU	Inhibitory	31.61 μM
BSK_BE3C_uPAR	Lung	Human	5329	PLAUR	Inhibitory	31.45 μM
BSK_CASM3C_HLADR	Vascular	Human	3122	HLA-DRA	Inhibitory	25.42 μM
BSK_CASM3C_IL6	Vascular	Human	3569	IL6	Inhibitory	31.88 μM
BSK_CASM3C_IL8	Vascular	Human	3576	CXCL8	Inhibitory	35.52 μM
BSK_CASM3C_LDLR	Vascular	Human	3949	LDLR	Inhibitory	34.83 μM
BSK_CASM3C_MCP1	Vascular	Human	6347	CCL2	Inhibitory	33.53 μM
BSK_CASM3C_MCSF	Vascular	Human	1435	CSF1	Inhibitory	26.54 μM
BSK_CASM3C_MIG	Vascular	Human	4283	CXCL9	Inhibitory	33.94 μM
BSK_CASM3C_SAA	Vascular	Human	6288	SAA1	Inhibitory	30.61 μM
BSK_CASM3C_TissueFactor	Vascular	Human	2152	F3	Inhibitory	32.65 μM
BSK_CASM3C_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	34.45 μM
BSK_CASM3C_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	26.54 μM
BSK_KF3CT_ICAM1	Skin	Human	3383	ICAM1	Inhibitory	18.91 μM
BSK_KF3CT_IL1a	Skin	Human	3552	IL1A	Inhibitory	30.41 μM
BSK_KF3CT_MCP1	Skin	Human	6347	CCL2	Inhibitory	20.0 μM
BSK_KF3CT_TIMP2	Skin	Human	7077	TIMP2	Inhibitory	29.18 μM
BSK_LPS_CD40	Vascular	Human	958	CD40	Inhibitory	38.79 μM
BSK_LPS_Eselectin	Vascular	Human	6401	SELE	Inhibitory	36.99 μM
BSK_LPS_IL1a	Vascular	Human	3552	IL1A	Inhibitory	33.18 μM
BSK_LPS_IL8	Vascular	Human	3576	CXCL8	Inhibitory	30.87 μM
BSK_LPS_MCP1	Vascular	Human	6347	CCL2	Inhibitory	31.54 μM
BSK_LPS_MCSF	Vascular	Human	1435	CSF1	Inhibitory	31.68 μM
BSK_LPS_TNFa	Vascular	Human	7124	TNF	Inhibitory	32.98 μM
BSK_LPS_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	28.22 μM
BSK_SAg_CD38	Vascular	Human	952	CD38	Inhibitory	36.59 μM
BSK_SAg_CD40	Vascular	Human	958	CD40	Inhibitory	31.97 μM
BSK_SAg_CD69	Vascular	Human	969	CD69	Inhibitory	36.81 μM
BSK_SAg_Eselectin	Vascular	Human	6401	SELE	Inhibitory	20.0 μM
TOX21_GR_BLA_Agonist_ratio	Cervix	Human	2908	NR3C1	Gain	20.26 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	28.82 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.81 μM
TOX21_AR_BLA_Agonist_ratio	Kidney	Human	367	AR	Gain	51.02 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	0.97 μM
TOX21_Aromatase_LUC_Antagonist	Breast	Human	1588	CYP19A1	Loss	1.28 μM
TOX21_ERa_BLA_Agonist_ratio	Kidney	Human	2099	ESR1	Gain	50.93 μM
TOX21_ERa_BLA_Antagonist_ratio	Kidney	Human	2099	ESR1	Loss	64.45 μM
TOX21_GR_BLA_Agonist_ratio	Cervix	Human	2908	NR3C1	Gain	18.32 μM
TOX21_PPARg_BLA_Agonist_ratio	Kidney	Human	5468	PPARG	Gain	24.42 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.59 μM
TOX21_VDR_BLA_Antagonist_ratio	Kidney	Human	1591\|7421	CYP24A1\|VDR	Loss	0.86 μM
TOX21_RORg_LUC_CHO_Antagonist	Ovary	Chinese hamster	6097	RORC	Loss	0.71 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	25.39 μM
TOX21_AP1_BLA_Agonist_ratio	Cervix	Human	2353\|3725	FOS\|JUN	Gain	0.25 μM
TOX21_TSHR_HTRF_Antagonist_ratio	Kidney	Human	7253	TSHR	Loss	88.0 μM
TOX21_CAR_LUC_Antagonist	Liver	Human	9970	NR1I3	Loss	27.98 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2	Breast	Human	2099	ESR1	Loss	39.83 μM
TOX21_AChE_Fluor_Antagonist	Bone	Human	43	ACHE	Loss	0.53 μM
TOX21_PXR_LUC_Agonist	Liver	Human	8856	NR1I2	Gain	0.82 μM
TOX21_TRHR_HEK293_Agonist	Kidney	Human	7201	TRHR	Gain	49.66 μM
TOX21_TRHR_HEK293_Antagonist	Kidney	Human	7201	TRHR	Loss	44.54 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	1.21 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	0.85 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	0.46 μM
TOX21_AChE_ms_Antagonist		Human	43	ACHE	Loss	69.22 μM
TOX21_AChE_Antagonist		Human	43	ACHE	Loss	53.0 μM
TOX21_hERG_U2OS_Antagonist	Bone	Human	3757	KCNH2	Loss	34.37 μM
TOX21_ARE_KS_LUC_Agonist	Skin	Human	4780	NFE2L2	Gain	0.77 μM
TOX21_GNRHR_HEK293_Agonist	Kidney	Human	2798	GNRHR	Gain	48.01 μM
TOX21_KISS1R_HEK293_Agonist	Kidney	Human	84634	KISS1R	Gain	60.7 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	0.65 μM
TOX21_ERa_BLA_Antagonist_ratio	Kidney	Human	2099	ESR1	Loss	68.85 μM
TOX21_GR_BLA_Agonist_ratio	Cervix	Human	2908	NR3C1	Gain	27.85 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	59.14 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.23 μM
TOX21_VDR_BLA_Antagonist_ratio	Kidney	Human	1591\|7421	CYP24A1\|VDR	Loss	0.58 μM
TOX21_RORg_LUC_CHO_Antagonist	Ovary	Chinese hamster	6097	RORC	Loss	0.56 μM
TOX21_AP1_BLA_Agonist_ratio	Cervix	Human	2353\|3725	FOS\|JUN	Gain	0.29 μM
TOX21_TSHR_HTRF_Antagonist_ratio	Kidney	Human	7253	TSHR	Loss	70.59 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2	Breast	Human	2099	ESR1	Loss	19.63 μM
TOX21_PXR_LUC_Agonist	Liver	Human	8856	NR1I2	Gain	0.49 μM
TOX21_TRHR_HEK293_Agonist	Kidney	Human	7201	TRHR	Gain	30.25 μM
TOX21_TRHR_HEK293_Antagonist	Kidney	Human	7201	TRHR	Loss	31.35 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	0.78 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	0.5 μM
TOX21_AChE_ms_Antagonist		Human	43	ACHE	Loss	85.05 μM
TOX21_AChE_Antagonist		Human	43	ACHE	Loss	55.65 μM
TOX21_GNRHR_HEK293_Agonist	Kidney	Human	2798	GNRHR	Gain	43.3 μM
TOX21_KISS1R_HEK293_Agonist	Kidney	Human	84634	KISS1R	Gain	64.96 μM

No ToxCast endpoints for intended target type: Molecular messenger

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	0.48 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist	Bone	Human	367	AR	Gain	50.0 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist	Bone	Human	367	AR	Loss	0.56 μM
APR_HepG2_MitoticArrest_24hr	Liver	Human	3020	H3-3A	Activatory	23.68 μM
APR_HepG2_P-H2AX_24hr	Liver	Human	3014	H2AX	Inhibitory	21.48 μM
APR_HepG2_StressKinase_24hr	Liver	Human	3725	JUN	Activatory	19.75 μM
OT_AR_ARSRC1_0480	Kidney	Human	367\|6714	AR\|SRC	Gain	71.7 μM
OT_AR_ARSRC1_0960	Kidney	Human	367\|6714	AR\|SRC	Gain	67.47 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	21.47 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	65.88 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	29.63 μM
TOX21_p53_BLA_p2_ratio	Intestinal	Human	7157	TP53	Gain	31.76 μM
TOX21_p53_BLA_p4_ratio	Intestinal	Human	7157	TP53	Gain	19.8 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	35.9 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	58.72 μM
TOX21_FXR_BLA_Agonist_ratio	Kidney	Human	9971	NR1H4	Gain	18.18 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	0.54 μM
TOX21_PPARd_BLA_Antagonist_ratio	Kidney	Human	5467	PPARD	Loss	0.75 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	31.6 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	33.06 μM
TOX21_ESRE_BLA_Agonist_ratio	Cervix	Human	22926	ATF6	Gain	52.46 μM
TOX21_NFkB_BLA_agonist_ratio	Cervix	Human	4790	NFKB1	Gain	28.0 μM
TOX21_H2AX_HTRF_CHO_Agonist_ratio	Ovary	Chinese hamster	3014	H2AX	Gain	0.97 μM
TOX21_HDAC_LUC_Antagonist	Colon	Human	3065	HDAC1	Loss	43.3 μM
TOX21_HRE_BLA_Agonist_ratio	Cervix	Human	3091	HIF1A	Gain	48.4 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	0.05 μM
TOX21_ARE_BLA_Agonist_ratio	Liver	Human	4780	NFE2L2	Gain	0.33 μM
TOX21_HSE_BLA_Agonist_ratio	Cervix	Human	3297	HSF1	Gain	18.99 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	72.17 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	0.35 μM
TOX21_PPARd_BLA_Antagonist_ratio	Kidney	Human	5467	PPARD	Loss	0.83 μM
TOX21_p53_BLA_p2_ratio	Intestinal	Human	7157	TP53	Gain	52.35 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	70.21 μM
TOX21_p53_BLA_p4_ratio	Intestinal	Human	7157	TP53	Gain	57.42 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	79.81 μM
TOX21_ESRE_BLA_Agonist_ratio	Cervix	Human	22926	ATF6	Gain	60.83 μM
TOX21_H2AX_HTRF_CHO_Agonist_ratio	Ovary	Chinese hamster	3014	H2AX	Gain	0.77 μM
TOX21_HDAC_LUC_Antagonist	Colon	Human	3065	HDAC1	Loss	41.1 μM
TOX21_HRE_BLA_Agonist_ratio	Cervix	Human	3091	HIF1A	Gain	32.27 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	0.17 μM

ToxCast endpoints for intended target type: Cellular

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
APR_HepG2_MicrotubuleCSK_24hr	Liver	Human	7846	TUBA1A	Activatory	28.92 μM

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.